Clinical Evidence

Clinical Evidence

A Clinically Proven Solution With more than 6.9 million treatments delivered, over 188,000 patients treated, and 1,100 practices across the U.S., NeuroStar® Advanced Therapy is the market leader in clinical practice.

Only NeuroStar has established durability*** through 12 months.6,9

Long-term post acute treatment.6,9

Graph of long term post-acute treatment rates for patients.

NeuroStar clinical studies have shown a low discontinuation rate of only 5%.9,15

NeuroStar has the world’s largest depression Outcomes Registry**. By clinician rating, 83% of patients responded to an acute course of NeuroStar, and 62% achieved remission.3,18

83% response and 62% remission rates for patients.3,18

Graph of response and remission rates for patients.

“These findings further emphasize the very real impact NeuroStar can have for people who are searching for depression relief now. We’re grateful for our NeuroStar providers who work tirelessly to transform the lives of their patients.”

—Keith Sullivan, President & CEO

NeuroStar is backed by an unmatched body of clinical evidence. Our commitment to advancing the science of TMS and neurohealth has been demonstrated in over 65 clinical studies with more than 1,900 patients.

For more information on Neuronetics’ proven NeuroStar solution, contact us today.

Contact Neuronetics